Shares of Pfizer Inc. PFE dropped 0.81% to $29.42 Friday, on what proved to be an all-around mixed trading session for the ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for ...

Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Pfizer reported at #ESMO that an experimental antibody helped cancer patients with a condition known as cachexia.

Shares of Pfizer Inc. PFE shed 0.27% to $29.75 Wednesday, on what proved to be an all-around dismal trading session for the ...

Acepodia, a start-up developing cell therapies, is collaborating with Pfizer Ignite, which will offer research and development support for drug candidates targeting autoimmune diseases. Acepodia is ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

Inspired by Pfizer’s response to the COVID pandemic, Miguel Agreda ’25 brought his skills as a joint-degree MBA/MPH student ...